PRESS RELEASE

Maastricht, The Netherlands, June 28th 2021

BioActor is thrilled to be an industrial partner of the INIMINI project, in partnership with Wageningen University & Research. The project “INIMINI-health: immune- and microbiota-competent intestine-on-a-chip to study health-promoting nutrition and drugs”, funded by Health Holland, aims to integrate microbiota and immunity into a miniaturized assay.

The intestine-on-a-chip model is a promising technology to revolutionize the currently used in vitro methods to better emulate the complex in vivo human intestinal physiology, providing an alternative for animal models in which species differences and ethical concerns are problematic. With this innovative tool, it will be possible to explore food interventions (and food-drug interactions) that can be used to prevent a compromised intestinal immune system and/or to treat the consequences.

The project consortium is a unique combination of knowledge partners (TO2 and academic institutes),  six industry partners (Dutch and international) along the value chain, and the Dutch Maag Lever Darm Stichting (MLDS) as the key patient organization. BioActor will provide its knowledge on the physiological effects of flavonoids and arabinoxylans on the gut microbiota and the immune system.

This embodies the ‘quadruple helix’ approach that contributes to the overarching mission of “vital functioning citizens in a healthy economy”.

 

 About BioActor

BioActor, based in Maastricht, Netherlands, is a life science company that develops and markets proprietary bioactives for the nutrition & healthcare industries. The company focuses on clinically validated innovative bioactives that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer real health benefits to the consumer.

For further information, see www.bioactor.com